



PRESTO

P2X Receptors as Therapeutic Opportunity

PUBLICATIONS

1. Zanoni M, Pegoraro A, Adinolfi E, De Marchi E. Emerging roles of purinergic signalling in anti-cancer therapy resistance. **Frontiers in Cell and Developmental Biology**, **2022**;10:1006384. doi: 10.3389/fcell.2022.1006384
2. Demeules M, Scarpitta A, Hardet R, Gondé H, Abad C, Blandin M, Menzel S, Duan Y, Rissiek B, Magnus T, Mann AM, Koch-Nolte F, Adriouch S. Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo. **Frontiers in Immunology**, **2022**, 13:1012534. doi: 10.3389/fimmu.2022.1012534.
3. Janho Dit Hreich S, Juhel T, Hofman P, Vouret-Craviari V. Protocol for evaluating in vivo the activation of the P2RX7 immunomodulator. **Biological Procedures Online**, **2023**. 25:1. doi: 10.1186/s12575-022-00188-6.
4. Škrbić R, Travar M, Stojiljković MP, Djuric DM, Suručić R. Folic Acid and Leucovorin Have Potential to Prevent SARS-CoV-2-Virus Internalization by Interacting with S-Glycoprotein/Neuropilin-1 Receptor Complex. **Molecules**, **2023**, 28:2294. doi: 10.3390/molecules28052294.
5. Jooss T, Zhang J, Zimmer B, Rezzonico-Jost T, Rissiek B, Felipe Pelczar P, Seehusen F, Koch-Nolte F, Magnus T, Zierler S, Huber S, Schemann M, Grassi F, Nicke A. Macrophages and glia are the dominant P2X7-expressing cell types in the gut nervous system-No evidence for the role of neuronal P2X7 receptors in colitis. **Mucosal Immunology**, **2023**, 16(2):180. doi: 10.1016/j.mucimm.2022.11.003.
6. Penolazzi L, Notarangelo MP, Lambertini E, Vultaggio-Poma V, Tarantini M, Di Virgilio F, Piva R. Unorthodox localization of P2X7 receptor in subcellular compartments of skeletal system cells **Frontiers in Cell and Developmental Biology**, **2023**;11:1180774. doi: 10.3389/fcell.2023.1180774.
7. Janho Dit Hreich S, Hofman P, Vouret-Craviari V. The role of IL-18 in P2RX7-mediated antitumor immunity. **International Journal of Molecular Sciences**, **2023**, 24:9235. doi: 10.3390/ijms24119235.
8. Zabłocki K, Górecki DC. The Role of P2X7 Purinoceptors in the Pathogenesis and Treatment of Muscular Dystrophies. **International Journal of Molecular Sciences**, **2023**, 24:9434. doi: 10.3390/ijms24119434.
9. Di Virgilio F, Vultaggio-Poma V, Falzoni S, Giuliani AL. The Coming of Age of the P2X7 Receptor in Diagnostic Medicine. **International Journal of Molecular Sciences**, **2023**, 24:9465. doi: 10.3390/ijms24119465
10. Sluyter R, Adriouch S, Fuller SJ, Nicke A, Sophocleous RA, Watson D. Animal Models for the Investigation of P2X7 Receptors. **International Journal of Molecular Sciences**, **2023**, 24:8225. doi: 10.3390/ijms24098225.
11. Vultaggio-Poma V, Scussel Bergamin L, Falzoni S, Tarantini M, Giuliani AL, Sandonà D, Polverino De Laureto P, Di Virgilio F. Fetal bovine serum contains biologically available ATP. **Purinergic Signalling**, **2023**, doi: 10.1007/s11302-023-09941-2.

List published in July 2023.

Year 1: Grant Period, November 1st, 2022 – October 31st, 2023